Roche CEO Schwan Speaks as Drugmaker Boosts Outlook for Third Time

The transcript covers an interview with Roche's CEO, Severin Schwan, discussing the company's strong business performance, particularly in the third quarter, driven by new medicines for severe diseases. It addresses the impact of biosimilars on European sales and the anticipated effects in the US. The conversation also touches on the ongoing deal with Spark Therapeutics, regulatory challenges, and potential US tariffs on Swiss medicines. Schwan emphasizes the importance of innovation and the need for reform in US healthcare to reduce high out-of-pocket expenses for patients.

What was the main reason for the unexpected positive demand for Roche's new medicines?

• Increased marketing efforts

• Level of differentiation and benefits for severe diseases

• Lower pricing strategy

• Expansion into new markets

What challenge is Roche facing in the European market?

• High competition from local companies

• Regulatory issues

• Decline in sales due to biosimilars

• Lack of new product launches

What is Roche's expectation regarding the impact of biosimilars in the US?

• Positive impact on sales

• No impact expected

• Immediate increase in market share

• Significant impact anticipated

What is the status of Roche's deal with Spark Therapeutics?

• Confident to close by the end of the year

• Already completed

• Deal has been canceled

• Delayed until next year

What is a potential concern for Roche regarding the Spark Therapeutics deal?

• Lack of investor interest

• Competition from other bidders

• Strong performance in hemophilia business

• High transaction costs

What is Roche's stance on potential US tariffs on Swiss medicines?

• Expecting government intervention

• Planning to relocate operations

• Not worried due to US operations

• Concerned about significant impact

What does Roche identify as a key issue in the US healthcare system?

• Limited access to healthcare facilities

• High out-of-pocket expenses for patients

• Lack of innovation

• Insufficient insurance coverage